BioRestorative Therapies Statistics
BioRestorative Therapies (9OF0) Stock Statistics & Valuation Metrics
Total Valuation
BioRestorative Therapies has a market cap or net worth of EUR 1.89M. The enterprise value is EUR 1.27M.
- Market Cap
- EUR 1.89M
- Enterprise Value
- EUR 1.27M
Share Statistics
BioRestorative Therapies has 1,381,128 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,381,128
- Owned by Insiders
- ―
- Owned by Institutions
- 0.15%
Financial Efficiency
BioRestorative Therapies’s return on equity (ROE) is -39.92 and return on invested capital (ROIC) is -4386.10%.
- Return on Equity (ROE)
- -39.92
- Return on Assets (ROA)
- -3.49
- Return on Invested Capital (ROIC)
- -4386.10%
- Return on Capital Employed (ROCE)
- -43.86
- Revenue Per Employee
- 25.69K
- Profits Per Employee
- -1.02M
- Employee Count
- 14
- Asset Turnover
- 0.09
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BioRestorative Therapies is -0.07. BioRestorative Therapies’s PEG ratio is -0.00.
- PE Ratio
- -0.07
- PS Ratio
- 5.90
- PB Ratio
- 0.45
- Price to FCF
- -0.18
- Price to Operating Cash Flow
- -0.11
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, BioRestorative Therapies had revenue of 359.70K and earned -14.24M in profits. Earnings per share was -31.60.
- Revenue
- 359.70K
- Gross Profit
- 335.86K
- Operating Income
- -15.65M
- Pretax Income
- -14.24M
- Net Income
- -14.24M
- EBITDA
- -14.03M
- Earnings Per Share (EPS)
- -31.60
Cash Flow
In the last 12 months, operating cash flow was -11.82M and capital expenditures -79,675, giving a free cash flow of -11.90M billion.
- Operating Cash Flow
- -11.82M
- Free Cash Flow
- -11.90M
- Free Cash Flow per Share
- -13.42
Dividends & Yields
BioRestorative Therapies pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -541.86%
- Earnings Yield
- -784.61%
Stock Price Statistics
- Beta
- 0.46
- 52-Week Price Change
- -89.04%
- 50-Day Moving Average
- 0.13
- 200-Day Moving Average
- 0.23
- Relative Strength Index (RSI)
- 25.31
- Average Volume (3m)
- 10.00K
Important Dates
BioRestorative Therapies upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 18, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
BioRestorative Therapies as a current ratio of 0.84, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.84
- Quick Ratio
- 0.84
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.11
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BioRestorative Therapies has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BioRestorative Therapies EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.07.
- EV to Sales
- -2.47
- EV to EBITDA
- 0.08
- EV to Free Cash Flow
- 0.07
- EV to Operating Cash Flow
- 0.07
Balance Sheet
BioRestorative Therapies has EUR 3.59M in cash and marketable securities with EUR 34.52K in debt, giving a net cash position of EUR 3.56M billion.
- Cash & Marketable Securities
- EUR 3.59M
- Total Debt
- EUR 34.52K
- Net Cash
- EUR 3.56M
- Net Cash Per Share
- EUR 2.58
- Tangible Book Value Per Share
- EUR 2.84
Margins
Gross margin is 92.09%, with operating margin of -3975.00%, and net profit margin of -3089.55%.
- Gross Margin
- 92.09%
- Operating Margin
- -3975.00%
- Pretax Margin
- -3089.55%
- Net Profit Margin
- -3089.55%
- EBITDA Margin
- -3030.70%
- EBIT Margin
- -3089.55%
Analyst Forecast
The average price target for BioRestorative Therapies is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- -12.63%
- EPS Growth Forecast
- 31.46%
